GPP Forum Article - Frida Dunger Johnsson, Executive Director, IFPA
Frida Dunger Johnsson, Executive Director of IFPA and panelist at the generalized pustular psoriasis (GPP) Forum, reflects on a momentous day
Search
Living with GPP
Video content showing a patient’s perspective of living with generalized pustular psoriasis (GPP), a rare skin condition
World-Psoriasis-Day-IFPA-Interview
Interview with the International Federation of Psoriasis Associations (IFPA)
Spesolimab (BI 655130)
Spesolimab (BI 655130): IL36R antibody
Unmet needs in Generalized Pustular Psoriasis (GPP)
Live well with Generalized Pustular Psoriasis (GPP)
The GPP Forum Report
The generalized pustular psoriasis (GPP) Forum Report summarizes and highlights the important moments form the multistakeholder GPP Forum
SPEVIGO approved expanded indications China US
SPEVIGO® approved for expanded indications in China and the US
Generalised-Pustular-Psoriasis-Infographic
What is GPP? GPP is a rare and chronic autoinflammatory skin disease with recurrent episodes of exacerbations or flares
SPEVIGO®
SPEVIGO® (spesolimab) is a novel, humanized, selective antibody for the treatment of generalized pustular psoriasis (GPP) flares.
The GPP Charter
The GPP Charter defines a collaborative approach to identifying common goals for the GPP community
GPP: there is more than you see
Generalized Pustular Psoriasis is a rare neutrophilic skin condition. Watch an animation to learn about its recurrent nature and how it affects people
The Unwearable Collection™
The Unwearable Collection™ was created to bring the physical and emotional burden of living with GPP to life.
GPP
GPP
Spesolimab (BI 655130)
Spesolimab (BI 655130): IL36R antibody
Spesolimab (BI 655130)
Spesolimab (BI 655130): IL36R antibody Netherton Syndrome
Spesolimab (BI 655130)
Spesolimab (BI 655130): IL36R antibody
The Unwearable Collection™: Fashion Inspired by GPP
An introduction to The Unwearable Collection™: fashion inspired by the experiences of living with GPP, designed by Bart Hess
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award
SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
We support non-linear career paths.
Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”
Boehringer Ingelheim 2022 half year results
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
EURORDIS Award
EURORDIS has selected Boehringer Ingelheim for the first time as recipient of the prestigious Black Pearl Award 2020
The Unwearable Collection™ Evolution
Get ready for the next stage of The Unwearable Collection™
Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80-85% of all lung cancer cases. Find out more about testing and treatment here.
India: Many positive developments for the population
A conversation with interim country manager Sandip Agrawal about a young and growing country